Volpara Health enters agreement to be acquired by Lunit, Inc.
The transaction is expected to accelerate Volpara's ability to serve its purpose of saving families from cancer. With the support of Lunit's in-house radiologists and complementary technologies, Volpara's repository of more than 100 million images would be strategically augmented by additional AI expertise and solutions. Together the companies plan to explore new opportunities in global markets and offer a broader portfolio of products in Volpara's largest market, the US.
CEO and Managing Director of Volpara,
The offer will be implemented by way of a scheme of arrangement ("Scheme"), a common process for acquisitions in
See full details in the ASX announcement.
About Volpara Health Technologies Limited (ASX: VHT)
Volpara Health Technologies makes software to save families from cancer. Volpara helps leading healthcare providers positively impact their patients and families around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain mammogram quality, provide objective mammogram density, and speed up and smooth the arduous reporting necessary for mammography accreditation.
Volpara's focus on customer value means that its AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, Volpara's software helps streamline operations and provides key performance insights that support continuous quality improvement.
A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. With a strong sales base in
For more information, visit www.volparahealth.com.
About Lunit (KRX:328130.KQ)
Founded in 2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Lunit is committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers.
As a medical AI company grounded on clinical evidence, Lunit's findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and global conferences, including ASCO and RSNA.
After receiving FDA clearance and the CE Mark, Lunit's flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/volpara-health-enters-agreement-to-be-acquired-by-lunit-inc-302014778.html
SOURCE Volpara Health, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Select Water stock surges 28% on Pilot Water acquisition deal
- Hafnia stock falls after increasing stake in Torm to 19.85%
- Form 8.5 (EPT/RI)-Tribal Group Plc
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share